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CRISPR/Cas9 is now used widely to genetically modify the genomes of various species.
The ability of CRISPR/Cas9 to delete DNA sequences and correct DNA mutations opens
up a new avenue to treat genetic diseases that are caused by DNA mutations. In
this review, we describe the advantages of using CRISPR/Cas9 to engineer genomic
DNAs in animal embryos, as well as in specific regions or cell types in the brain. We also
discuss how to apply CRISPR/Cas9 to establish animal models of neurodegenerative
diseases, such as Parkinson’s and Huntington’s disease (HD), and to treat these
disorders that are caused by genetic mutations.
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THE DEVELOPMENT AND APPLICATION OF CRISPR/Cas9
CRISPR/Cas9, a recent addition to our tools for genome editing, has led to a revolution in biological
research. CRISPR was originally reported as a set of short repeats located downstream of the iap
gene in E. coli (Ishino et al., 1987). As more similar repeat elements were reported over years,
Mojica et al. (2000) termed it as Short Regularly Spaced Repeats (SRSR). Jansen et al. (2002) then
reported that several clusters of signature CRISPR-associated (Cas) genes were well conserved and
typically adjacent to the repeat elements. Later, a series of studies uncovered the efficient antiviral
defense mechanism of the CRISPR system (Jansen et al., 2002; Barrangou et al., 2007; Brouns et al.,
2008; Karginov and Hannon, 2010). In this system, the non-coding CRISPR array is transcribed
and cleaved within direct repeats into short crRNAs containing individual spacer sequences, which
direct the nuclease Cas9 to targeted sequences of genomic DNA. The nuclease Cas9 then cuts both
strands of DNA precisely, and the damaged DNA is repaired via non-homologous end joining
(NHEJ) or homology-directed repair (HDR), thereby resulting in gene disruptions and inactivation
of the targeted gene. Jinek et al. (2012) fused a crRNA containing the targeting guide sequence
to a tracrRNA, called a single guide RNA (gRNA), to facilitate DNA cleavage by CRISPR/Cas9.
CRISPR/Cas9 has now been used for genome editing in a variety of species (Hsu et al., 2014; Sander
and Joung, 2014), especially in non-human primates that do not have embryonic stem cells for
genomic manipulation (Niu et al., 2014; Chen et al., 2015) and human tripronuclear (3PN) zygotes
(Liang et al., 2015).
Another powerful application of the CRISPR/Cas9 system is based on its ability to target
many genomic loci simultaneously for studying gene function on a global scale (Koike-Yusa
et al., 2014; Shalem et al., 2014; Zhou et al., 2014) which is certainly an advantage over RNAi
and its limitations, such as low efficiency and specificity in genome-scale screens. Based on
the DNA binding property of CRISPR/Cas9, researchers have also developed catalytically dead
Cas9 (dCas9) to act as transcriptional or epigenetic regulators (Larson et al., 2013; Qi et al., 2013)
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or to couple Cas9 to fluorescence as DNA-binding reporters for
live imaging (Chen et al., 2014).
The power of CRISPR/Cas9 to edit the genome holds
great promise for treating human diseases caused by genetic
DNA mutations. Recently, the UK Human Fertilization and
Embryology Authority (HFEA) granted scientists in London
permission to genetically edit human embryos within the range
of research ethics (Callaway, 2016). Although there are still
social and ethical issues that remain to be resolved, it is
clear we must consider how to use CRISPR/Cas9 to treat
human diseases in the future. In this review, we will focus
on the application of CRISPR/Cas9 to animal models of
neurodegenerative diseases.
USE OF CRISPR/Cas9 TO GENERATE
ANIMAL MODELS OF
NEURODEGENERATIVE DISEASES
Neurodegenerative diseases, such as Parkinson’s disease (PD)
and Huntington’s disease (HD), share common features: namely,
the age-dependent accumulation of misfolded proteins and
selective neurodegeneration. For example, in PD, the presence
of cytoplasmic misfolded proteins, termed Lewy bodies, which
contain ubiquitinated alpha-synuclein, parkin, synphilin, and
neurofilaments, are the pathological hallmark of this disease in
patient brains. In the brains of HD patients, on the other hand,
there are aggregates or inclusions formed in an age-dependent
manner by mutant huntingtin with an expanded polyQ tract (Li
and Li, 2011).
Animal models are highly valuable and have been used
extensively to investigate neurological disorders and to find
therapeutic targets for them. Because many neurodegenerative
diseases can be caused by genetic DNA mutations, the ability
of CRISPR/Cas9 to directly target any gene in one or two
alleles of the embryonic genome opens up a new avenue
for using this new technology to generate animal models
of neurodegenerative diseases. The traditional gene targeting
technology made it difficult to establish large animal models
of human diseases due to the lack of embryonic stem cell
lines. Since large animals are closer to humans, their disease
models may more faithfully mimic the clinical symptoms of
patients and are important for exploring the mechanisms
and treatment of both neuropsychiatric disorders and age-
related neurodegenerative diseases. For example, because the
loss of function of the Parkin and Pink1 genes can cause
PD, CRISPR/Cas9-mediated mutations can mimic knockout
of the Parkin and/or Pink1 gene. CRISPR/Cas9 was found to
functionally disrupt the dystrophin gene in founder monkeys
and causes the same muscle atrophy phenotype seen in patients
(Chen et al., 2015). Thus, when both alleles are mutated by
CIRSPR/Cas9, the complete loss of Parkin or Pink1 will mimic
the geneticmutations in PD patients. Also, because CRISPR/Cas9
can target multiple genes in the same cells, deletion of the
Parkin and Pink1 genes will allow for studies of synergistic
effects of loss of these important genes. Indeed, CRISPR/Cas9
has been used to generate pig models of PD by targeting the
genes for Parkin, Pink1 and DJ1 (Zhou et al., 2015; Wang et al.,
2016).
In addition to genome editing in germline cells, CRISPR/Cas9
can efficiently target genes in somatic tissues, such as neurons
in the brain (Incontro et al., 2014; Platt et al., 2014; Straub
et al., 2014; Swiech et al., 2015; Heidenreich and Zhang,
2016; Walters et al., 2016). In PD patients, a progressive loss
of dopaminergic neurons in the substantia nigra is a key
pathological feature. Thus, gRNAs and Cas9 can be delivered
to the substantia nigra of animal brains by a viral system to
investigate the effect of Parkin or Pink1 loss in adult brains. This
approach is particularly useful for investigating the age-related
neuropathology in PD.
Also, Cas9-mediated knock-in mutations within the genome
can help generate animal models of those neurodegenerative
diseases caused by a gain of toxicity of mutant proteins. For
example, PD can be caused by mutations in α-synuclein, and
HD is caused by polyQ expansion in huntingtin. Co-injection of
Cas9/gRNAs with exogenous donor fragments carrying mutant
sequences can replace the endogenous gene with mutant DNAs,




The animal models created by CRISPR/Cas9 normally carry
mutations in endogenous genes and therefore provide better
models to mimic human diseases than transgenic animals that
express mutant genes under exogenous promoters. These new
animal models will be highly valuable for identifying therapies
using drugs or chemicals. Although CRSIPR/Cas9 has been
used widely in the generation of a variety of cellular or animal
models of human diseases, it is particularly important that
we develop CRISPR/Cas9 as a therapeutic tool for treating
human diseases. For example, CRISPR/Cas9 can be used to
correct the causative gene mutations in monogenic recessive
disorders or to inactivate themutated allele in dominant-negative
disorders to achieve therapeutic benefits. Recently, three groups
independently reported that CRISPR/Cas9 was able to snip out
a faulty exon of the dystrophin gene to generate a shortened
but functional version of dystrophin to treat mice with muscular
dystrophy (Long et al., 2016; Nelson et al., 2016; Tabebordbar
et al., 2016). Although the mature muscle cells of adults lack
the ability for cell division and have different DNA repair
machinery than dividing cells, CRISPR/Cas9 gene editing can
occur in skeletal muscle to functionally repair DNA mutations.
In addition, CRISPR/Cas9 was used to correct the mutant Crygc
gene that causes cataracts in zygotes from mice via HDR with
an endogenous WT allele (Wu et al., 2013). All these findings
suggest that CRISPR/Cas9 can modify the genome in any type
of cell.
For neurodegenerative diseases, CRISPR/Cas9 can also be
a powerful tool to eliminate the expression of mutant genes
and therefore can alleviate the neuropathology caused by DNA
mutations. For example, HD is caused by polyQ expansion in
huntingtin, and selective targeting of the mutant huntingtin gene
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via CRISPR/Cas9 can be done in specific types of vulnerable
neurons in the brain. Similarly, for transgenic PD animal
models that express mutant α-synuclein, CRISPR/Cas9 can be
designed to deplete the expression of mutant genes via NHEJ,
which can lead to gene inactivation, in dopaminergic neurons.
Furthermore, the ability of CRISPR/Cas9 to replace the mutant
gene via HDR with normal DNA sequences can also lead to
the genetic correction of DNA mutations in HD and PD animal
models. Although the efficiency of such gene replacement is low
at present, the rapidly developing CRISPR/Cas9 system offers
a promising approach to generate knock-in models of human
diseases.
CHALLENGES FOR CRISPR/Cas9
Despite the power of CRISPR/Cas9 for genome editing, there
are still many challenges to be overcome when applying it to
generate and treat animal models of human diseases. Because
genome editing by CRISPR/Cas9 relies on approximately 23
base pair matches (Hsu et al., 2014), possible off-target effects
have been considered an important issue. However, some studies
reported that Cas9 could tolerate mismatches, depending on
their distribution and number (Hsu et al., 2013; Mali et al.,
2013; Fu et al., 2014). Also, a lower Cas9 concentration
can decrease the off-target effect at the expense of on-target
efficiency (Hsu et al., 2013). Thus, using specific gRNAs and
appropriate Cas9 concentrations should minimize the off-targets
and increase the specificity of CRSIPR/Cas9-mediated gene
targeting.
The second issue with CRISPR/Cas9 is mosaic mutations,
which may result from the prolonged expression of Cas9
after cell division or may be due to a slow rate of cleavage
by Cas9 nuclease. Alternatively, differential DNA repair and
non-homozygous recombination activities in zygotes and
divided embryonic cells can also influence genetic mutation
rates and mosaicism. Direct delivery of Cas9 protein into cells
has also been tried and showed high target efficiency, but
still resulted in mosaic mutations (Kim et al., 2014; Sung
et al., 2014). Precise control of Cas9 nuclease expression at the
transcriptional and translational levels in zygotes may reduce
mosaic mutations.
Another challenge for CRISPR/Cas9 is the low rate of
homologous recombination. Generally, HDR takes place
in the synthesis (S) and the premitotic (G2) phases (Heyer
et al., 2010), whereas NHEJ occurs in the growth 1 (G1) and
the mitotic (M) phases (Daley and Sung, 2014). Although
CRISPR/Cas9-mediated indel mutations via NHEJ have
high efficiency, the HDR rate is relatively low. Suppression
of NHEJ key molecules is found to increase the HDR
rate by CRISPR/Cas9 (Chu et al., 2015; Maruyama et al.,
2015). Further evolution of the CRISPR/Cas9 system to
increase targeting specificity and efficiency is expected to
improve the knock-in rate and the application of this genetic
engineering tool to treat neurodegenerative diseases in the
future.
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